Peptide quality verification: from COA to release decision
"99% pure" is the most quoted and least examined number in this market. Quality is not a percentage on a certificate — it is a set of questions the certificate either answers or avoids. This is the framework we use to decide whether a lot is releasable.
The premise: a COA is an argument, not a fact
A certificate of analysis is a document that claims a set of results. Whether those results are true depends on three things: whether the sample tested was the lot shipped, whether the methods were capable, and whether the document was produced when the lot was made — not assembled later from a template.
Our position: a COA without batch linkage is not evidence. Everything else in this guide is downstream of that. If the batch number on the certificate cannot be tied to the vial label and the production record, the analytical numbers are decoration.
The six questions
Why these six and not twenty
Every releasable lot should be able to answer these six questions with data. If a supplier answers four and hand-waves two, you are buying an assumption.
| Question | Method | Failure mode if unanswered |
|---|---|---|
| Is it the right molecule? | ESI-MS or MALDI-TOF | Wrong peptide, truncated sequence or modified variant |
| How much of it is the target peak? | RP-HPLC with stated method | Co-eluting impurities inflate the purity number |
| How much water is in the powder? | Karl Fischer | Weighing error; accelerated hydrolysis |
| How much is actually peptide? | Assay / net peptide content | You pay for counter-ions and water |
| Is the solution clean? | Visual inspection; subvisible particle count where relevant | Particulates interfere with assays and cell work |
| Is it biologically clean? | Endotoxin / bioburden (where claimed) | False results in sensitive cell systems |
Reading the chromatogram like an auditor
Method first, then the trace
Do not start with the percentage. Start with the method: column, dimensions, mobile phase, gradient, wavelength, injection volume. A purity figure without these is not reproducible and cannot be compared across suppliers.
Then look at the trace itself:
- Baseline: is integration drawn on a stable baseline, or does it cut through drift?
- Impurity peaks: are minor peaks visible and integrated, or suppressed?
- Peak shape: fronting or tailing suggests column overload or secondary interactions.
- Retention time: consistent with the method and the compound's hydrophobicity?
- Scale: is the y-axis expanded to hide small peaks? A chromatogram should show the full range.
Our rule: a chromatogram with no visible impurities at all is a prompt to check the integration, not a reason to celebrate. Real synthesis leaves a profile.
The net-content cost trap (worked example)
Buyers compare price per vial. The economically meaningful number is price per milligram of peptide, not per milligram of powder. Consider two illustrative lots of the same nominal product (assumptions stated, not measured data):
| Parameter | Lot A | Lot B |
|---|---|---|
| Nominal fill | 10 mg | 10 mg |
| HPLC purity (area %) | 98.0% | 96.5% |
| Water content | 3% | 8% |
| Counter-ion / salt fraction (assumed) | 6% | 6% |
| Net peptide (approx.) | 10 × 0.98 × 0.97 × 0.94 ≈ 8.9 mg | 10 × 0.965 × 0.92 × 0.94 ≈ 8.3 mg |
| Price per vial (illustrative) | $120 | $108 |
| Price per mg net peptide | $13.5 | $13.0 |
In this example the cheaper vial is only marginally cheaper per milligram of actual peptide — and it carries more water, which is a stability risk. The calculation is illustrative; the point is structural: purity percentage alone does not tell you what you are paying for. Ask for water content and net peptide content, then compare cost per mg of peptide.
Lot consistency beats any single result
A single lot can be excellent by luck. A process is only trustworthy if consecutive lots land inside the same window. This is why we treat trend data as the primary quality signal and the single COA as the entry ticket.
What to trend:
- Retention time and impurity profile (HPLC)
- Observed mass and adduct pattern (MS)
- Water content (Karl Fischer)
- Net peptide content (assay)
- Appearance and reconstitution behaviour
If a supplier cannot provide two or three consecutive lot COAs, you are not buying a process — you are buying a series of independent purchases that happen to share a product name. Lot-to-lot consistency covers the statistics and the retention-sample practice.
Third-party testing: when it is worth it, when it is theatre
The sampling question decides it
Independent testing adds value when it answers a question the supplier cannot self-certify convincingly — identity on a high-value lot, endotoxin for cell work, or a disputed result. It adds little when it simply repeats the supplier's own HPLC on a sample the supplier selected.
Our rule: use third-party testing as a tie-breaker and a dispute tool, not as a substitute for supplier qualification. Using a third-party laboratory explains sampling and chain-of-custody.
The release decision
| Condition | Decision |
|---|---|
| Batch-linked COA + chromatogram + MS + water content, inside spec | Release |
| Data complete but one result marginal | Conditional release after confirmatory retest |
| Missing identity or chromatogram | Hold — do not use |
| Batch linkage broken | Reject — document cannot be tied to goods |
| Consecutive lots drifting | Escalate — process issue, not a lot issue |
What this framework deliberately excludes
It does not attempt to certify sterility, and it does not convert research-grade material into a pharmaceutical-grade claim. Those are different standards with different evidence. Conflating them is one of the most common — and most dangerous — errors in this market.
The Author's Take
Position. Buyers should stop asking "what is the purity?" and start asking "what is the evidence chain?" A supplier that can walk you from batch record to chromatogram to shipped vial is in a different category from one that emails a PDF with a number on it.
Reasoning. Purity is easy to state and hard to verify; traceability is hard to fake at scale. The suppliers who invest in records do so because their process depends on them — which is exactly the behaviour you want to rely on when something goes wrong.
Disclosure. We sell research peptides and compete on documentation. We also reject lots that fail this framework, which occasionally costs us orders.
Frequently asked
Is purity the same for every batch?
No. Purity is measured per lot and stated on that lot's COA. A single clean result does not describe the process.
What does a batch COA include?
Identity by MS, purity by HPLC with chromatogram and method, water content by Karl Fischer, appearance, and where applicable net peptide content.
Do you provide third-party testing?
Yes, on request and at additional cost. It is most useful as a tie-breaker on a specific lot, not as a substitute for supplier qualification.
How do I compare net peptide content between suppliers?
Ask for water content and assay content, then compare price per milligram of net peptide rather than price per vial.
Sources & evidence
The methods and acceptance concepts referenced in this guide map to published standards. Specific limits must come from your own specification, not from this page.
- Method validation: ICH Q2(R1) — ICH quality guidelines.
- Specification setting: ICH Q6B — same ICH page.
- Water content: USP <731> Loss on Drying / Karl Fischer methods — USP.
- Particulate matter: USP <788> — same USP source.
- Endotoxin: USP <85> Bacterial Endotoxins Test — same USP source.
- Reference molecular weights: PubChem — semaglutide CID 56843331; tirzepatide CID 166567236.
- Chinese Pharmacopoeia (ChP 2020), Part IV: General Chapter 0512 (HPLC), 0832 (loss on drying), 0903 (particulate matter), 1143 (bacterial endotoxins) — cited by chapter number; the official edition is the authoritative text.
The net-content worked example is illustrative: the percentages are stated assumptions, not measured results from any lot.
Products referenced in this guide
- Tirzepatide — batch COA with HPLC and MS
- Semaglutide — batch COA with HPLC and MS
- Retatrutide — batch COA with HPLC and MS
- Research peptides — BPC-157, TB-500, CJC-1295, Ipamorelin
- Cosmetic peptides — GHK-Cu, glutathione
- Quality framework — how we release batches
- Testing methods — HPLC, MS, Karl Fischer
Cluster: the quality library
This pillar is the decision framework; the cluster articles are the method detail. A practical reading order:
- Verifying purity before you buy — the entry point
- Reading HPLC chromatograms — method and integration
- Identity by mass spectrometry — what MS proves
- MS/MS sequence confirmation — going further
- COA red flags — spotting recycled certificates
- Water content by Karl Fischer — the hidden variable
- Net content and cost per mg — the economic view
- Lot-to-lot consistency — trend over snapshot
- Stability studies — the time dimension
- Degradation pathways — what failure looks like
- Synthesis impurities — where they come from
- Counter-ion forms — acetate vs TFA
- Residual solvents — the overlooked test
- Elemental impurities — metals and catalysts
- Endotoxin and bioburden — when it matters
- Subvisible particles — solution clarity
- Aggregate analytics — SEC, DLS, AUC
- Method validation — is the method capable?
- HPLC method design — building the method
- Reference standards — the anchor
- Sampling and release — from receipt to trend
- Appearance inspection — the first check
- Extractables and leachables — packaging risk
- Cross-contamination — line-level risk
- Data integrity — can the record be trusted?
- Third-party testing — the tie-breaker